Israel Englander Cue Biopharma, Inc. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 358,974 shares of CUE stock, worth $391,281. This represents 0.0% of its overall portfolio holdings.

Number of Shares

358,974

Previous 493,987 27.33%

Holding current value

$391,281

Previous $612,000 55.56%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.45 - $1.08 $60,755 - $145,814	-135,013 Reduced 27.33%	358,974 $272,000
Q2 2024 Aug 14, 2024	BUY	$1.24 - $2.18 $163,552 - $287,535	131,897 Added 36.43%	493,987 $612,000
Q1 2024 May 15, 2024	BUY	$1.77 - $3.09 $153,007 - $267,115	86,445 Added 31.36%	362,090 $684,000
Q4 2023 Feb 14, 2024	BUY	$1.72 - $3.1 $168,222 - $303,192	97,804 Added 55.0%	275,645 $727,000
Q2 2023 Aug 14, 2023	SELL	$3.11 - $4.91 $518,657 - $818,845	-166,771 Reduced 48.39%	177,841 $649,000
Q1 2023 May 15, 2023	SELL	$2.41 - $3.74 $70,781 - $109,843	-29,370 Reduced 7.85%	344,612 $1.23 Million
Q4 2022 Feb 14, 2023	SELL	$2.39 - $3.95 $158,698 - $262,283	-66,401 Reduced 15.08%	373,982 $1.07 Million
Q3 2022 Nov 14, 2022	SELL	$2.23 - $3.37 $360,863 - $545,340	-161,822 Reduced 26.87%	440,383 $982,000
Q2 2022 Aug 15, 2022	BUY	$2.49 - $5.92 $1.2 Million - $2.85 Million	481,735 Added 399.88%	602,205 $1.5 Million
Q1 2022 May 16, 2022	BUY	$4.41 - $12.28 $27,633 - $76,946	6,266 Added 5.49%	120,470 $588,000
Q4 2021 Feb 14, 2022	BUY	$10.86 - $17.85 $343,729 - $564,970	31,651 Added 38.34%	114,204 $1.29 Million
Q3 2021 Nov 15, 2021	SELL	$10.06 - $15.3 $1.48 Million - $2.25 Million	-146,780 Reduced 64.0%	82,553 $1.2 Million
Q2 2021 Aug 16, 2021	BUY	$10.9 - $14.53 $1.65 Million - $2.19 Million	150,957 Added 192.61%	229,333 $2.67 Million
Q1 2021 May 17, 2021	SELL	$11.2 - $16.09 $3.18 Million - $4.57 Million	-284,147 Reduced 78.38%	78,376 $956,000
Q4 2020 Feb 16, 2021	BUY	$11.12 - $16.4 $2.02 Million - $2.99 Million	182,058 Added 100.88%	362,523 $4.54 Million
Q3 2020 Nov 16, 2020	SELL	$15.05 - $23.54 $618,825 - $967,917	-41,118 Reduced 18.56%	180,465 $2.72 Million
Q2 2020 Aug 14, 2020	BUY	$12.7 - $30.73 $2.81 Million - $6.81 Million	221,583 New	221,583 $5.43 Million
Q4 2019 Feb 14, 2020	SELL	$7.06 - $17.47 $98,310 - $243,269	-13,925 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$6.78 - $9.28 $94,411 - $129,223	13,925 New	13,925 $117,000
Q2 2019 Aug 14, 2019	SELL	$7.18 - $9.65 $79,683 - $107,095	-11,098 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$4.7 - $9.29 $52,160 - $103,100	11,098 New	11,098 $86,000

Others Institutions Holding CUE

# of Institutions

Shares Held

14.1M

Call Options Held

14.4K

Put Options Held

2.6K

View Full List

About Cue Biopharma, Inc.

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.6M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

More about CUE

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account